Related Experiment Videos
Local control with multimodality therapy for stage 4 neuroblastoma.
S L Wolden1, S V Gollamudi, B H Kushner
1Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. woldens@mskcc.org
Summary
This study shows that 21 Gy hyperfractionated radiotherapy, combined with surgery and chemotherapy, provides durable local control for Stage 4 neuroblastoma patients. The treatment was well-tolerated with no acute radiotherapy complications observed.
Area of Science:
- Pediatric Oncology
- Radiation Oncology
- Surgical Oncology
Background:
- Stage 4 neuroblastoma is a complex pediatric cancer requiring multimodal treatment approaches.
- Optimizing local control is crucial for improving survival outcomes in these high-risk patients.
Purpose of the Study:
- To assess the effectiveness of 21 Gy hyperfractionated radiotherapy for local control in Stage 4 neuroblastoma.
- To evaluate this radiotherapy regimen when used alongside surgery and intensive systemic therapy.
Main Methods:
- 47 children (ages 1-10) with Stage 4 neuroblastoma received dose-intensive chemotherapy, maximal surgical debulking, and 21 Gy hyperfractionated radiotherapy (1.5 Gy BID).
- Radiotherapy fields covered the primary tumor, regional nodes, and a 3-cm margin.
- Treatment was followed by autologous bone marrow transplantation or immunotherapy consolidation.
Main Results:
- Five-year actuarial rates for local control, progression-free survival, and overall survival were 84%, 40%, and 45%, respectively.
- Of 45 patients achieving remission pre-radiotherapy, only one experienced isolated local relapse.
- No acute radiotherapy-related complications were reported.
Conclusions:
- 21 Gy hyperfractionated radiotherapy is a safe and effective component of multimodal therapy for Stage 4 neuroblastoma.
- This regimen achieves durable local control in the majority of patients.
- The combination of radiotherapy, surgery, and systemic therapy is well-tolerated.